Do complement inhibitors and FcRn blockers help patients with myasthenia gravis?
For people with generalized myasthenia gravis (gMG) who have acetylcholine receptor (AChR) antibodies, two newer drug classes — complement inhibitors and FcRn blockers — have been shown to help. Complement inhibitors (like eculizumab, ravulizumab, zilucoplan) block part of the immune system that attacks the nerve-muscle connection. FcRn blockers (like efgartigimod, rozanolixizumab, batoclimab) lower the level of harmful antibodies in the blood. Both types are approved or in advanced testing for gMG, and research shows they can improve daily function and reduce muscle weakness.
What the research says
A large meta-analysis of 6 randomized trials (739 patients) and 4 long-term extension studies (588 patients) found that both complement inhibitors and FcRn blockers significantly improve outcomes compared to placebo or standard care 57. Patients taking these drugs had an average improvement of 1.7 points on the MG-ADL scale (a measure of daily living activities) and 2.7 points on the QMG scale (a measure of muscle strength) 57. The odds of achieving a meaningful improvement in MG-ADL were 2.7 times higher, and for QMG 3.5 times higher, with these drugs 57. The analysis also showed reduced risk of clinical worsening and need for rescue therapy 57.
Specific drugs have shown benefit in real-world studies. For example, efgartigimod (an FcRn blocker) helped 80% of 81 Chinese gMG patients achieve a meaningful MG-ADL improvement after one treatment cycle 3. A post-hoc analysis of the phase 3 ADAPT trial found that efgartigimod worked equally well in men and women 4. Complement inhibitors are also approved for gMG: eculizumab (and its biosimilar Epysqli) is indicated for AChR antibody-positive gMG in adults 1.
Both drug classes are considered effective and fast-acting, with promising safety profiles 6. However, they are typically used after standard treatments (like steroids or immunosuppressants) have not worked well enough, and their availability may depend on local guidelines and insurance coverage 6.
What to ask your doctor
- Based on my AChR antibody status and symptom severity, could a complement inhibitor or FcRn blocker be an option for me?
- What are the potential side effects of these drugs, and how do they compare to my current treatment?
- How long does it typically take to see improvement with these medications?
- Are there any specific tests or monitoring needed before or during treatment?
- What is the cost and insurance coverage for these therapies in my area?
This question is drawn from common patient questions about Rheumatology and answered using cited medical research. We do not provide individualized advice.